Dimitri-Pinheiro Sofia, Soares Raquel, Barata Pedro
Hospital Centre of Vila Nova de Gaia/Espinho, Vila Nova de Gaia, Portugal.
Department of Biomedicine, Unit of Biochemistry, Faculty of Medicine, University of Porto, Porto, Portugal.
Allergy Rhinol (Providence). 2020 Mar 13;11:2152656720911605. doi: 10.1177/2152656720911605. eCollection 2020 Jan-Dec.
Recently, multiple studies regarding the human microbiota and its role on the development of disease have emerged. Current research suggests that the nasal cavity is a major reservoir for opportunistic pathogens, which can then spread to other sections of the respiratory tract and be involved in the development of conditions such as allergic rhinitis, chronic rhinosinusitis, asthma, pneumonia, and otitis media. However, our knowledge of how nasal microbiota changes originate nasopharyngeal and respiratory conditions is still incipient. Herein, we describe how the nasal microbiome in healthy individuals varies with age and explore the effect of nasal microbiota changes in a range of infectious and immunological conditions. We also describe the potential health benefits of human microbiota modulation through probiotic use, both in disease prevention and as adjuvant therapy. Current research suggests that patients with different chronic rhinosinusitis phenotypes possess distinct nasal microbiota profiles, which influence immune response and may be used in the future as biomarkers of disease progression. Probiotic intervention may also have a promising role in the prevention and adjunctive treatment of acute respiratory tract infections and allergic rhinitis, respectively. However, further studies are needed to define the role of probiotics in the chronic rhinosinusitis.
最近,出现了多项关于人类微生物群及其在疾病发展中作用的研究。目前的研究表明,鼻腔是机会性病原体的主要储存库,这些病原体随后可传播至呼吸道的其他部位,并参与诸如过敏性鼻炎、慢性鼻-鼻窦炎、哮喘、肺炎和中耳炎等病症的发展。然而,我们对于鼻腔微生物群变化如何引发鼻咽部和呼吸道疾病的了解仍处于初始阶段。在此,我们描述了健康个体的鼻腔微生物群如何随年龄变化,并探讨了在一系列感染性和免疫性病症中鼻腔微生物群变化的影响。我们还描述了通过使用益生菌调节人类微生物群在疾病预防和辅助治疗方面的潜在健康益处。目前的研究表明,不同慢性鼻-鼻窦炎表型的患者具有独特的鼻腔微生物群特征,这些特征会影响免疫反应,未来可能用作疾病进展的生物标志物。益生菌干预在急性呼吸道感染的预防和过敏性鼻炎的辅助治疗中可能也具有前景。然而,需要进一步研究来确定益生菌在慢性鼻-鼻窦炎中的作用。